27746-02-7

Usage

Uses

Used in Organic Synthesis:
4-BROMOPYRROLE-2-CARBOXYLIC ACID is used as a key intermediate for the synthesis of various organic compounds due to its unique structure and reactivity.
Used in Medicinal Chemistry:
4-BROMOPYRROLE-2-CARBOXYLIC ACID is used as a building block for the development of pharmaceuticals, leveraging its anti-inflammatory and antifungal activities to create new therapeutic agents.
Used in Pharmaceutical Industry:
4-BROMOPYRROLE-2-CARBOXYLIC ACID is used as a precursor in the synthesis of drugs, contributing to the creation of novel medications with potential applications in treating inflammation and fungal infections.
Used in Agrochemical Industry:
4-BROMOPYRROLE-2-CARBOXYLIC ACID is used as a starting material for the production of agrochemicals, potentially aiding in the development of new pesticides or fungicides to protect crops from diseases.

InChI:InChI=1/C5H4BrNO2/c6-3-1-4(5(8)9)7-2-3/h1-2,7H,(H,8,9)/p-1

Upstream product

• 1057111-70-2 C₁₄H₁₁BrF₆N₂O₄ 
• 35302-72-8 pyrrol-2-yl trichloromethyl ketone 
• 72652-32-5 1-(4-bromo-1H-pyrrol-2-yl)-2,2,2-trichloroethanone 

Downstream Products

• 1338811-32-7 4-bromo-N-(2,4-dimethoxybenzyl)-N-(3-(4-nitrophenyl)prop-2-ynyl)-1H-pyrrole-2-carboxamide 
• 1338811-18-9 4-bromo-N-(3-(3-cyano-4-fluorophenyl)prop-2-ynyl)-N-(2,4-dimethoxybenzyl)-1H-pyrrole-2-carboxamide 
• 1069472-63-4 4-bromo-N-(3-bromo-4-methoxyphenethyl)-1H-pyrrole-2-carboxamide 
• 1174650-73-7 4-bromo-N-(3-bromo-4-(2-(pyrrolidin-1-yl)ethoxy)phenethyl)-1H-pyrrole-2-carboxamide 
• 1069472-64-5 4-bromo-N-(3-bromo-4-hydroxyphenethyl)-1H-pyrrole-2-carboxamide 
• 934995-58-1 Dispyrin 

Relevant academic research and scientific papers

Production of anticancer polyenes through precursor-directed biosynthesis

The biosynthesis of the pyrrolyl moiety of the fungal metabolite rumbrin originates from pyrrole-2-carboxylic acid. In an effort to produce novel derivatives with enhanced biological activity a series of substituted pyrrole-2-carboxylates were synthesised

ISOLATION, STRUCTURE DETERMINATION, SYNTHESIS AND BIOACTIVITY OF DAMIPIPECOLIN AND DAMITURICIN

Two new bromopyrrole alkaloids, compounds (1) and (2), have been isolated from the Mediterranean sponge Axinella damicυrnis, and their structure established through spectroscopic methods. Compounds (1) and (2 )display a modulating effect of the serotonin

Damipipecolin and damituricin, novel bioactive bromopyrrole alkaloids from the Mediterranean sponge Axinella damicornis

Two new bromopyrrole alkaloids, damipipecolin (1) and damituricin (2), have been isolated from the Mediterranean sponge Axinella damicornis, and their structures established through spectroscopic methods. Compounds 1 and 2 extend the structural variety of

MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1a, R1b, R1c, Q, A, R3, W, D and R2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

PHENYL-3-{ (3- (1H- PYRROL- 2 -YL) - [1 , 2 , 4] 0XADIAZ0L-5-YL] PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention provides new compounds of formula (I) as positive allosteric modulators of metabotropic receptors - subtype 5 ("mGluR5") which are useful for the treatment or prevention of central nervous system disorders such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other central or peripheral nervous system disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. The invention is also directed to pharmaceutical compounds and compositions in the prevention or treatment of such diseases in which mGluKi is involved. W represents (C4-C7)cycloalkyl, (C3-C7)heterocycloalkyl , (C3-C7)heterocycloalkyl-(C1-C3)alkyl or (C3-C7)heterocycloalkenyl ring; represents a (C5-C7)heteroeycloalkyl, (C5-C7)heterocycloalkeiiyl ring or a heteroaryl group of formula (a), (b), (c), (d), (e), (f), (g), (i). Q denotes a cycloalkyl, an aryl or heteroaryl group of formula (j), (k), (l), (m), (n). A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR8C(=O)-, -NR8C(=O)-O-, -NR8C(=O)-NR9, NR8S(=O)2-, -C(=O)NR8-, -O-C(=O)NR8-, -S-, -S(=O)-, -S(=O)2-, -S(C=O)2NR8-, -C(=0)-0-, -0-C(=0)-, -C(=NR8)NR9-, C(C=NOR8)NR9- , -NR8C(=NOR9)-, =N-0-, -0-N=CH- or a group aryl or heteroaryl of formula, (o), (p), (q), (r), (s), (t), (u), (v), (w), (x). The other substituents are defined in the claims.